AI healthcare IT market expected to cross $1.7B in 2019

The market for AI healthcare IT applications is expected to cross $1.7 billion by the end of next year, according to Forbes.

In a recent report, Forbes unveiled its top healthcare predictions for 2019, and the use of AI in clinical and non-clinical spaces is expected to provide a big boost in the industry, leading to the market growth. Productivity is also expected to rise 10 percent to 15 percent thanks to AI platforms being used with select healthcare workflows.  

“Throughout 2019, AI and machine learning will further evolve human and machine interaction. More specifically, AI will begin to see fruition, particularly in the imaging diagnostic, drug discovery and risk analytics applications,” the report stated.

Other healthcare predictions for 2019 include:

  • 15 percent of global healthcare spending will be tied to value-based models
  • Digital health tech catering to out of hospital will grow by 30 percent and cross $25 billion
  • Asia becomes the new local innovation hub for global drug and device original equipment manufacturers
  • Analytics shifts from big data to meaningful small data by hospital specialty
  • Healthcare will be a dominate vertical in voice applications
  • Blockchain moves from hype to real initial commercial implementations generating returns on investment
  • Innovative private insurance models shake up healthcare payer industry

To read the full report, click the link below. 

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.